Journal of the European Academy of Dermatology and Venereology : JEADV
-
J Eur Acad Dermatol Venereol · Jul 2017
The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
Hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) is a rare, potentially fatal, bradykinin-mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United States as an acute therapy option for HAE attacks in adults. ⋯ These data form the first European cross-country comparison of disease characteristics and icatibant use in patients with C1-INH-HAE who are enrolled in IOS. International variation in icatibant practice and treatment outcomes across the six European countries assessed highlight the need to further investigate the range of country-specific parameters driving regional variations in icatibant use.
-
J Eur Acad Dermatol Venereol · Jul 2017
Letter Case ReportsPseudo-pitting of the nail in psoriasis.
-
J Eur Acad Dermatol Venereol · Jul 2017
The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
There is concern that increased bodyweight may impact efficacy of some therapies used to treat psoriasis. ⋯ Ixekizumab was efficacious in the treatment of moderate-to-severe psoriasis regardless of bodyweight. The safety profile of ixekizumab was also similar across bodyweight categories, and no safety signals were identified specific to any of the bodyweight categories.
-
J Eur Acad Dermatol Venereol · Apr 2017
Comparative StudyTreatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Biologics are effective for the treatment of psoriasis. However, treatment outcomes may differ among biologic-naive patients and those switched from previous biological therapies. ⋯ Contrary to etanercept, the efficacy of ixekizumab was similarly high in patients with and without previous exposure to biologics when administered 80 mg every 2 weeks.